AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02689986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Rituximab
Description: Bendamustine, Rituximab
Study NCT03533829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy®
Description: Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
Study NCT04861753 — intervention group
Intervention type: OTHER
Intervention: Reiki and back massage
Description: In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
Study NCT03513237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical dilation
Description: manual dilatation of the cervix using surgeon's finger.
Study NCT00834509 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: Use CPAP for 4-6 weeks as clinically prescribed.
Study NCT02931864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online mindfulness training
Description: 5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
Study NCT02931864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online mindfulness training
Description: 5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
Study NCT02931864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online symptom management
Description: 5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
Study NCT02931864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online symptom management
Description: 5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
Study NCT02478944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manometry
Description: Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
Study NCT02479620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL
Description: Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
Study NCT02712554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Description: 7.5 mg/325 mg/12.5 mg tablet
Study NCT02712554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M366
Description: 7.5 mg/325 mg tablet
Study NCT02712554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01316081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine
Description: Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets
Study NCT01316081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine
Description: Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets
Study NCT01875523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Study NCT02871011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Delivered as a footbath
Study NCT02435498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive website
Description: The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
Study NCT02871011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Delivered as a footbath
Study NCT03049059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Picosecond 1,064 nm laser
Description: Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
Study NCT03049059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% hydroquinone cream
Study NCT03049059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% hydroquinone cream
Study NCT01609556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
Study NCT03533829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music will be selected and listened to as a distraction before and during vaccination.
Study NCT02198547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Mg used with ropivacaine for sciatic nerve blick
Study NCT02198547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 7,5 mg/ml used for sciatic nerve block
Study NCT02592733 — intervention group
Intervention type: DEVICE
Intervention: CYDAR
Description: CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
Study NCT04551105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group X - Session 1
Description: Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS.
Study NCT04551105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group Y - Session 1
Description: Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS.
Study NCT04551105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group X - Session 2
Description: Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS.
Study NCT04551105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group Y - Session 2
Description: Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS.
Study NCT02939105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ CoolSculpting System
Description: The CoolSculpting device will be used to perform treatments.
Study NCT03105050 — intervention group
Intervention type: OTHER
Intervention: Access to bariatric surgery
Description: All countries representatives will be interviewed on their Healthcare systems
Study NCT03128749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013).
Study NCT03128749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
Study NCT03128749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
Study NCT02528292 — intervention group
Intervention type: PROCEDURE
Intervention: Synovial biopsy
Description: Ultrasound guided synovial biopsy of inflamed joint
Study NCT02528292 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF therapy
Description: Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
Study NCT01383941 — intervention group
Intervention type: DRUG
Intervention: Guidelines-based asthma and rhinitis/rhinosinusitis therapy
Description: All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
Study NCT02563041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% TSC
Description: The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
Study NCT02563041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
Study NCT01117311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNB on
Description: The implanted Vagal Nerve Blocker will be on at the time of study.
Study NCT01117311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNB off
Description: The implanted Vagal Nerve Blocker will be off at the time of study.
Study NCT01812044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: subtenons anesthetic - preservative-free bupivacaine 0.75%
Study NCT01812044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel
Study NCT02435498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: The online video will contain the same information within the website.
Study NCT02435498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
Study NCT03089502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
Study NCT04042259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abthera
Description: Negative Pressure Wound Therapy Device
Study NCT04042259 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open adbdomen for post-laparotomy without NPWT device
Description: Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
Study NCT03423914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
Study NCT03423914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only Writing
Description: Participants write about knowledge related to infant care during four days
Study NCT03296267 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastroduodenoscopy
Description: Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
Study NCT02552329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
Study NCT01306968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute).
Study NCT01306968 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham hyperbaric air
Description: A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
Study NCT04022759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual with Security Prime
Description: In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions.
Study NCT04022759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (Behavioural Activation)
Description: Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
Study NCT01441401 — intervention group
Intervention type: DRUG
Intervention: gabapentin
Description: According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
Study NCT01126359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
Study NCT01126359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
Study NCT01126359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Saline
Description: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
Study NCT01126359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Saline
Description: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
Study NCT01277107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaleplon AP formulation
Description: Gastric retentive dual release Zaleplon
Study NCT01277107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Identical placebo capsule
Study NCT00547209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: air
Description: 60% air combined with 40% oxygen for ventilation
Study NCT00547209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: 60% nitrous oxide combined with 40% oxygen for ventilation
Study NCT02343497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Study NCT02343497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01916759 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
Description: Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
Study NCT01812044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: topical control - 0.5 cc of Hypromellose 0.3% gel
Study NCT04117048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabPad® point-of-care
Description: All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
Study NCT04503707 — intervention group
Intervention type: DRUG
Intervention: Follitropin Delta
Description: The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
Study NCT02246231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR imaging
Study NCT04352621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
Study NCT04352621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Description: patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
Study NCT00742859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betrixaban
Description: orally, once daily for at least 3 months
Study NCT00742859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin will be prescribed by the investigator according to the standard of care.
Study NCT02630004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin oral gel 3%
Study NCT02630004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral gel
Study NCT04171089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child- Safety Plan Intervention
Description: The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.